The contract research and manufacturing organization announced its Buffalo, NY- based site has been selected to participate as a Dedicated Chemical Biology Consortium (CBC) Center for the National Cancer Institute (NCI) Experimental Therapeutics (NExT) Program.
The NExT Program is supported by the CBC and is focused on advancing new cancer therapeutics against novel molecular and genetic targets. It is centered at the Frederick National Laboratory for Cancer Research.
AMRI is participating in the consortium through a research subcontract from Leidos Biomedical Research, the prime contractor for the national lab.
“As a member of the consortium, Leidos will provide AMRI with discovery research projects for review. AMRI will provide a recommended work plan and budget for consideration,” Chris Conway, Senior Vice President, Discovery and Development, AMRI, told Outsourcing-Pharma.com.
“As work plans and budgets are approved, AMRI will collaborate with members of the consortium providing discovery research services according to the plan.”
According to Conway, AMRI will contribute its knowledge in reagent design and production, assay development,high throughput screening, structural biology, medicinal chemistry, computer aided drug design (CADD), compound profiling, in vitro ADMET and cancer cell biology - all "with the goal to advance early stage drug discovery projects through to the clinical candidate stage," he said.